Key result
Review traces the historical development of heparin and vitamin K antagonists in thrombosis management.
Why the study?
Heparin and vitamin K antagonists have long defined anticoagulant therapy, and understanding their development history informs current clinical practice.
A historical overview of the development of anticoagulants from discovery to clinical practice.
Historical context on heparin and VKAs frames new anticoagulant development; leaves open optimal integration into current practice.
For more than half a century, heparin and vitamin K antagonists have defined anticoagulant therapy for the short-term and long-term management, respectively, of thrombotic disorders of the venous system. The history of their development is instructive. In 1922, at the annual meeting of the American Physiological Society, William H. Howell of Johns Hopkins Medical School presented an extraction protocol for isolating heparin preparations. Dicoumarol, a bacterial antagonist of vitamin K in spoiled sweet clover, was recognized as the agent responsible for a fatal hemorrhagic disease in livestock by Karl Link and Wilhelm Schoeffel of the University of Wisconsin. In both . . .
No takes yet. Share an insight, caveat, or question.
Lohrmann et al. (2008) conducted a review in Thrombotic disorders of the venous system. Anticoagulants was evaluated. The article reviews the historical development of heparin and vitamin K antagonists for the management of thrombotic disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: